Skip to main content

Table 3 Comparison of outcomes for patients not treated with MTX (Group 1), treated with MTX by intramuscular injection (Group 2) or treated with MTX by intravenous injection (Group 3)

From: Management of Caesarean scar pregnancy with or without methotrexate before curettage: human chorionic gonadotropin trends and patient outcomes

 

Mean ± SD/Rate

P value

Group 1(n = 47)

Group 2(n = 46)

Group 3(n = 14)

 

Intraoperative blood loss (ml)

39.83 ± 16.96

55.33 ± 44.19

42.86 ± 22.68

0.066

Pregnancy tissue retained, n (%)

1(2.1%)

2(4.3%)

1(7.1%)

0.658

Hospital stay (days)

7.00 ± 2.29

9.59 ± 2.46

13.86 ± 3.88

<0.001